• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed

    2/2/21 4:20:42 PM ET
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PDLI alert in real time by email
    POS AM 1 a20210202s-8doc.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Document

    As filed with the Securities and Exchange Commission on February 2, 2021
    Registration No. 333-87957
    Registration No. 333-68314
    Registration No. 333-104170
    Registration No. 333-125906
    Registration No. 333-145262
    Registration No. 333-220370
    Registration No. 333-220435
    Registration No. 333-225534

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549


    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-87957
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-68314
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-104170
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-125906
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-145262
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-220370
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-220435
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225534

    UNDER THE SECURITIES ACT OF 1933

    PDL BioPharma, Inc.
    (Exact Name of Registrant as Specified in its Charter)
    Delaware94-3023969
    (State or Other Jurisdiction of(I.R.S. Employer
    Incorporation or Organization)Identification Number)
    59 Damonte Ranch Parkway, Suite B-375
    Reno, Nevada 89521
    (Address of Principal Executive Offices) (Zip code)
    (775) 832-8500
    (Registrant's Telephone Number, Including Area Code)

    1999 Stock Option Plan
    1999 Nonstatutory Stock Option Plan
    1993 Employee Stock Purchase Plan
    2002 Outside Directors Stock Option Plan
    2005 Equity Incentive Plan
    Amended and Restated 2005 Equity Incentive Plan
    Nonstatutory Inducement Stock Option Grant Notice and Nonstatutory Inducement Stock Option Agreement
    Inducement Restricted Stock Grant Notice and Inducement Restricted Stock Agreement
    (Full title of the Plans)

    Christopher L. Stone
    Vice President, General Counsel and Secretary
    59 Damonte Ranch Parkway, Suite B-375
    Reno, Nevada 89521
    (Name and address of agent for service)





    (775) 832-8500
    (Telephone Number, Including Area Code, of Agent for Service)

    Copy to:
    Karen E. Bertero
    Gibson, Dunn & Crutcher LLP
    333 South Grand Avenue
    Los Angeles, California 90071
    (213) 229-7000


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer¨Accelerated filer¨
    Non-accelerated filerý(Do not check if a smaller reporting company)Smaller reporting company¨
    Emerging growth company¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    PDL BioPharma, Inc. (the “Registrant”) is filing these Post-Effective Amendments (“Amendments”) to those certain Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by the Registrant, as follows (note that the share numbers listed below do not take into account any corporate actions, such as stock splits, taken in the interim):

    1.Registration Statement on Form S-8 (File No. 333-87957) for the registration of 1,925,000 shares of common stock of the Registrant, par value $0.01 (“Shares”), issuable under the 1999 Stock Option Plan and the 1999 Nonstatutory Stock Option Plan.
    2.Registration Statement on Form S-8 (File No. 333-68314) for the registration of 4,000,000 Shares issuable under the 1999 Stock Option Plan and the 1999 Nonstatutory Stock Option Plan.
    3.Registration Statement on Form S-8 (File No. 333-104170) for the registration of 3,480,000 Shares issuable under the 1999 Nonstatutory Stock Option Plan and the 2002 Outside Directors Stock Option Plan.
    4.Registration Statement on Form S-8 (File No. 333-125906) for the registration of 2,300,000 Shares issuable under the 2005 Equity Incentive Plan.
    5.Registration Statement on Form S-8 (File No. 333-145262) for the registration of 3,400,000 Shares issuable under the 2005 Equity Incentive Plan and the 1993 Employee Stock Purchase Plan.
    6.Registration Statement on Form S-8 (File No. 333-220370) for the registration of 1,000,000 Shares issuable under the Amended and Restated 2005 Equity Incentive Plan.
    7.Registration Statement on Form S-8 (File No. 333-220435) for the registration of 1,201,200 Shares issuable under the Nonstatutory Inducement Stock Option Grant Notice and Nonstatutory Inducement Stock Option Agreement and the Inducement Restricted Stock Grant Notice and Inducement Restricted Stock Agreement.
    8.Registration Statement on Form S-8 (File No. 333-225534) for the registration of 20,000,000 Shares issuable under the Amended and Restated 2005 Equity Incentive Plan.
    The offerings contemplated by the Registration Statements have been terminated in connection with the Registrant’s previously disclosed voluntary plan of dissolution. In accordance with the undertaking contained in the Registration Statements (pursuant to Item 512(a)(3) of Regulation S-K), the Registrant hereby removes from registration any securities that were registered but unsold under the Registration Statements. Accordingly, these Amendments are being filed to deregister any securities covered by the above referenced plans which remain unissued as of the date of this filing.





    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Reno, State of Nevada, on this 2nd day of February, 2021.


    PDL BIOPHARMA, INC.
    By:
    /s/ Dominique Monnet
    Dominique Monnet
    President and Chief Executive Officer





    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dominique Monnet, Christopher L. Stone and Nathan Kryszak, and each of them, as his true and lawful attorney-in-fact and agent, with full and several power of substitution and resubstitution and to act without the others, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each such attorney-in-fact and agent full power and authority to do so and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each such attorney-in-fact and agent, or their substitute or resubstitute, each acting alone, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, the following persons have signed this Post-Effective Amendment No. 1 to the Registration Statements in the capacities and on the date(s) indicated.

    SignatureTitleDate
    /s/ Dominique Monnet
    President, Chief Executive Officer and DirectorFebruary 2, 2021
    Dominique Monnet
    (Principal Executive Officer)
    /s/ Edward A. Imbrogno, CPAVice President and Chief Financial OfficerFebruary 2, 2021
    Edward A. Imbrogno, CPA
    (Principal Financial Officer and Principal Accounting Officer)
    /s/ Elizabeth O’FarrellDirectorFebruary 2, 2021
    Elizabeth O’Farrell
    /s/ Alan BazaarDirectorFebruary 2, 2021
    Alan Bazaar
    /s/ Natasha A. HerndayDirectorFebruary 2, 2021
    Natasha A. Hernday
    /s/ John P. McLaughlinDirectorFebruary 2, 2021
    John P. McLaughlin


    Get the next $PDLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PDLI
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

      SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive

      12/11/20 8:00:00 AM ET
      $XOMA
      $PDLI
      $ALPN
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PDLI
    SEC Filings

    See more
    • SEC Form SC TO-I/A filed

      SC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/19/21 5:13:05 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:29 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:31 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PDLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/12/21 3:20:51 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/11/21 4:22:46 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PDLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: L.P. Capital Point Silver bought $383,475 worth of Common Stock (187,061 units at $2.05)

      4 - PDL BIOPHARMA, INC. (0000882104) (Issuer)

      2/3/21 5:57:54 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care